Prevention of portal vein thrombosis with anticoagulant therapy in patients with hepatic cirrhosis

INTERVENTION: Experimental arm: Enoxaparin (Sanofi Aventis, Milan) subcutaneously at a dose of 4000 IU/day for 1 year. Control arm: No treatment. CONDITION: Advanced stage cirrhosis ; Digestive System ; Other and unspecified cirrhosis of liver PRIMARY OUTCOME: Prevention of portal or mesenteric vein thrombosis SECONDARY OUTCOME: 1. Occurrence or recurrence of liver decompensation, defined as development of ascites, PSE, portal hypertensive bleeding, spontaneous bacterial peritonitis, or systemic infection; 2. Overall and transplant‐free survival INCLUSION CRITERIA: 1. Age =18 years old 2. Cirrhosis of any etiology 3. Child‐Pugh score between B7 to C10 3. No evidence of PVT or spleno‐mesenteric thrombosis by ultrasound evaluation and angio‐CT, hepatic, renal and coagulative evaluation